Our vision is to improve the treatment of severe diseases. Working with the medicines of the future we focus on oncology.

Human Health

Human HealthOur main goal is to develop new pharmaceuticals with high versatility were there are wide-spread medical needs.

Further reading »

Animal Health

Animal HealthAnimal Health develops and improves existing medical treatments focusing on oncology.

Further reading »

The Share

Latest News

Oasmia successfully completes private placement of SEK 50 million

July 3 2014
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of 2,500,000 new shares, providing the Company with SEK 50 million before transaction related costs.
Further reading »

Oasmia announces launch of private placement of new shares

July 2 2014
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces the launch of a private placement of new shares (“New Shares”) through a directed new share issue to international institutional investors and qualified investors in Sweden (the “Private Placement”).
Further reading »

Oasmia signs agreement for patented technology XR-17

June 25 2014
Today, the Swedish pharmaceutical company Oasmia Pharmaceutical AB (publ) (Oasmia) announced that a research agreement has been signed between Oasmia and a global pharmaceutical company. The agreement relates to the use of Oasmia’s patented nanoparticle formulation technology XR-17. The full terms of the agreement cannot be disclosed at this point in time.
Further reading »